used in 5 of 6 patients, and was well tolerated. Only 1 of 5 developed citrate gap, which resolved after adjusting citrate rate. No serious hemorrhagic events were observed. Two of 6 patients died (34%) e Case #1 due to SOS, and #5 due to systemic CMV infection. These corresponded to the patients with the highest FO. Conclusions: 1. Early initiation of CVVH may be a useful modality to prevent progressive fluid overload and maintain electrolyte and acid base balance in patients with FO and AKI following SOS.
Background: Transplant-associated thrombotic microangiopathy (TA-TMA) is a significant complication of hematopoietic stem cell transplantation and poses a challenge with diagnosis and management. Objectives: To report a case of TA-TMA in an allogeneic bone marrow transplant (BMT) patient and discuss diagnostic and management challenges. Design/Method: Case Report. Results: Seven year old female with B-thalassemia major who underwent 10/10 matched unrelated donor BMT. Her conditioning regimen included Busulfan, Fludarabine, Cyclophosphamide and ATG, graft versus host disease (GVHD) prophylaxis included cyclosporin and short course methotrexate. Post-transplant course was complicated by grade II acute GVHD, intracranial bleed, GI hemorrhage and pericardial effusion. She developed several episodes of acute kidney injury post-transplant with recovery of renal function back to baseline creatinine (0.3-0.5 mg/dL). Six months post transplant the patient developed hematuria and worsening proteinuria followed by intractable hypertension. Renal function gradually worsened with creatinine rising to w1.6 mg/dL and ended up with oliguria and fluid overload. In addition she developed hemolytic anemia, thrombocytopenia and peripheral blood schistocytes. Several measures were attempted to improve her renal function including stopping her calcineurin inhibitor, decreasing her diuretic regimen and stopping ACE inhibition. Renal biopsy was obtained and showed acute, severe thrombotic microangiopathy. Complement serologies (C3, C4, CFI, CFH levels and CFH autoantibody) were all normal or elevated. Hemodialysis, therapeutic plasma exchange and basiliximab were initiated. She received 2 doses of basiliximab and 10 treatments of plasma exchange, resulting in no response. The patient continued on thrice weekly dialysis. The patient tolerated dialysis with great difficulty complicated by bilateral eye pain, dizziness, extremity tingling and abdominal pain during her treatments. Finally the patient developed a syncopal event with mental status changes following one of her dialysis episodes. EEG confirmed seizure activity. Brain MRI showed diffuse white matter abnormality consistent with severe TMA. Given the patient's progressive worsening and extreme symptoms, Eculizumab was started. After 3 doses, she has begun to show signs of hematologic recovery with no signs of renal recovery. Her blood pressure remains very difficult to control. Conclusion: TA-TMA is an uncommon but significant complication of HSCT that presents significant diagnostic and management challenges. Even with accurate diagnosis (clinically and histologically), optimal treatment strategies remain elusive and the prognosis is poor. Introduction: Patients undergoing stem cell transplant (SCT) for treatment of hematologic malignancies have often been exposed to many blood products and may be alloimmunized. This makes platelet transfusions less effective, which is problematic in patients who are expected to be profoundly thrombocytopenic for 3-4 weeks. A second-line intervention in patients with refractory immune thrombocytopenia is continuous intravenous immune globulin (IVIG) at doses of 1 g/kg/day for 2 days and continuous platelet transfusion (1 pack of platelets/hour for 72 hours). This intervention has not been studied in allo-immunized SCT patients. Methods: A retrospective chart review was performed at the University of Wisconsin Hospital to assess outcomes of the continuous IVIG and platelet regimen in allo-immunized SCT patients from 1/1/2009 to 12/31/2012. All patients also received concurrent aminocaproic acid. Data points collected include primary hematologic diagnosis, indication for treatment, platelet response, clinical bleeding events, requirement for further therapy, other complications during hospital stay, and in-hospital mortality. Results: All of the patients had an increase in platelet count and there were no new bleeding events during the treatment period. The regimen does not appear to provide any longstanding improvement in platelet response. Discussion: Continuous IVIG and platelet transfusion does not appear to decrease allo-reactivity as had been hoped for. However, it does appear to be safe and does provide a 
